HC Wainwright Reiterates Buy Rating for BELLUS Health (TSE:BLU)

BELLUS Health (TSE:BLU – Get Rating)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued on Thursday, TipRanks reports. They currently have a C$16.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 50.38% from the stock’s previous close.

TSE BLU opened at C$10.64 on Thursday. The company’s 50-day moving average price is C$9.32 and its 200-day moving average price is C$8.77. The company has a current ratio of 15.23, a quick ratio of 14.76 and a debt-to-equity ratio of 0.30. The stock has a market cap of C$1.14 billion and a PE ratio of -9.17. BELLUS Health has a 12 month low of C$3.32 and a 12 month high of C$12.59.

BELLUS Health (TSE:BLU – Get Rating) last posted its quarterly earnings results on Wednesday, February 23rd. The company reported C($0.23) EPS for the quarter. The firm had revenue of C$0.05 million for the quarter. As a group, sell-side analysts forecast that BELLUS Health will post -1.67 earnings per share for the current year.

In other news, Senior Officer Francois Desjardins sold 14,053 shares of the company’s stock in a transaction dated Tuesday, March 22nd. The shares were sold at an average price of C$8.47, for a total value of C$118,989.56. Following the transaction, the insider now directly owns 81,722 shares in the company, valued at C$691,956.52.

BELLUS Health Company Profile (Get Rating)

BELLUS Health Inc, a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.

Featured Articles